Literature DB >> 25046253

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.

Kristina Althoff1, Sven Lindner, Andrea Odersky, Pieter Mestdagh, Anneleen Beckers, Sarah Karczewski, Jan J Molenaar, Anna Bohrer, Shirley Knauer, Frank Speleman, Matthias Epple, Diana Kozlova, Sena Yoon, Kwanghee Baek, Jo Vandesompele, Angelika Eggert, Alexander Schramm, Johannes H Schulte.   

Abstract

MicroRNAs (miRNAs) are deregulated in a variety of human cancers, including neuroblastoma, the most common extracranial tumor of childhood. We previously reported a signature of 42 miRNAs to be highly predictive of neuroblastoma outcome. One miRNA in this signature, miR-542, was downregulated in tumors from patients with adverse outcome. Reanalysis of quantitative PCR and next-generation sequencing transcript data revealed that miR-542-5p as well as miR-542-3p expression is inversely correlated with poor prognosis in neuroblastoma patients. We, therefore, analyzed the function of miR-542 in neuroblastoma tumor biology. Ectopic expression of miR-542-3p in neuroblastoma cell lines reduced cell viability and proliferation, induced apoptosis and downregulated Survivin. Survivin expression was also inversely correlated with miR-542-3p expression in primary neuroblastomas. Reporter assays confirmed that miR-542-3p directly targeted Survivin. Downregulating Survivin using siRNA copied the phenotype of miR-542-3p expression in neuroblastoma cell lines, while cDNA-mediated ectopic expression of Survivin partially rescued the phenotype induced by miR-542-3p expression. Treating nude mice bearing neuroblastoma xenografts with miR-542-3p-loaded nanoparticles repressed Survivin expression, decreased cell proliferation and induced apoptosis in the respective xenograft tumors. We conclude that miR-542-3p exerts its tumor suppressive function in neuroblastoma, at least in part, by targeting Survivin. Expression of miR-542-3p could be a promising therapeutic strategy for treating aggressive neuroblastoma.
© 2014 UICC.

Entities:  

Keywords:  Survivin; miR-542-3p; nanoparticles; neuroblastoma

Mesh:

Substances:

Year:  2014        PMID: 25046253     DOI: 10.1002/ijc.29091

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Extensive miRNA expression analysis in craniopharyngiomas.

Authors:  Jill Samis; Elio F Vanin; Simone Treiger Sredni; Maria de Fátima de Bonaldo; Fabricio F Costa; Tadanori Tomita; Reema Habiby; Donald Zimmerman; Marcelo B Soares
Journal:  Childs Nerv Syst       Date:  2016-06-07       Impact factor: 1.475

2.  Mutational dynamics between primary and relapse neuroblastomas.

Authors:  Alexander Schramm; Johannes Köster; Yassen Assenov; Kristina Althoff; Martin Peifer; Ellen Mahlow; Andrea Odersky; Daniela Beisser; Corinna Ernst; Anton G Henssen; Harald Stephan; Christopher Schröder; Lukas Heukamp; Anne Engesser; Yvonne Kahlert; Jessica Theissen; Barbara Hero; Frederik Roels; Janine Altmüller; Peter Nürnberg; Kathy Astrahantseff; Christian Gloeckner; Katleen De Preter; Christoph Plass; Sangkyun Lee; Holger N Lode; Kai-Oliver Henrich; Moritz Gartlgruber; Frank Speleman; Peter Schmezer; Frank Westermann; Sven Rahmann; Matthias Fischer; Angelika Eggert; Johannes H Schulte
Journal:  Nat Genet       Date:  2015-06-29       Impact factor: 38.330

3.  miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1.

Authors:  Long Yuan; Peng Yuan; Huijuan Yuan; Zhenlei Wang; Zengci Run; Guanglong Chen; Peng Zhao; Benling Xu
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

4.  Cedrol alleviates the apoptosis and inflammatory response of IL-1β-treated chondrocytes by promoting miR-542-5p expression.

Authors:  Wangchao Dong; Shanshan Wang; Weiqing Qian; Suming Li; Peimin Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-12-10       Impact factor: 2.416

Review 5.  Smart nanomaterials for cancer diagnosis and treatment.

Authors:  Ragini Singh; Ayush Sharma; Joel Saji; Akhela Umapathi; Santosh Kumar; Hemant Kumar Daima
Journal:  Nano Converg       Date:  2022-05-15

Review 6.  Targeting the apoptosis pathway to treat tumours of the paediatric nervous system.

Authors:  Marie-Claire Fitzgerald; Philip J O'Halloran; Niamh M C Connolly; Brona M Murphy
Journal:  Cell Death Dis       Date:  2022-05-14       Impact factor: 9.685

7.  MiR-542-3p Suppresses Neuroblastoma Cell Proliferation and Invasion by Downregulation of KDM1A and ZNF346.

Authors:  Qiang Wei; Zhao Guo; Dong Chen; Xinjian Jia
Journal:  Open Life Sci       Date:  2020-04-10       Impact factor: 0.938

Review 8.  Signaling by exosomal microRNAs in cancer.

Authors:  Germana Falcone; Armando Felsani; Igea D'Agnano
Journal:  J Exp Clin Cancer Res       Date:  2015-04-02

9.  MiR542-3p Regulates the Epithelial-Mesenchymal Transition by Directly Targeting BMP7 in NRK52e.

Authors:  Zhicheng Liu; Yuru Zhou; Yue Yuan; Fang Nie; Rui Peng; Qianyin Li; Zhongshi Lyu; Zhaomin Mao; Liyuan Huang; Li Zhou; Yiman Li; Jing Hao; Dongsheng Ni; Qianni Jin; Yaoshui Long; Pan Ju; Wen Yu; Jianing Liu; Yanxia Hu; Qin Zhou
Journal:  Int J Mol Sci       Date:  2015-11-24       Impact factor: 5.923

10.  Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.

Authors:  Yvonne Voges; Martin Michaelis; Florian Rothweiler; Torsten Schaller; Constanze Schneider; Katharina Politt; Marco Mernberger; Andrea Nist; Thorsten Stiewe; Mark N Wass; Franz Rödel; Jindrich Cinatl
Journal:  Cell Death Dis       Date:  2016-10-13       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.